156 related articles for article (PubMed ID: 31540746)
1. Gleason pattern 5 is associated with an increased risk for metastasis following androgen deprivation therapy and radiation: An analysis of RTOG 9202 and 9902.
Hamstra DA; Pugh SL; Lepor H; Rosenthal SA; Pienta KJ; Gomella L; Peters C; D'Souza DP; Zeitzer KL; Jones CU; Hall WA; Horwitz E; Pisansky TM; Souhami L; Hartford AC; Dominello M; Feng F; Sandler HM
Radiother Oncol; 2019 Dec; 141():137-143. PubMed ID: 31540746
[TBL] [Abstract][Full Text] [Related]
2. Gleason pattern 5 is the strongest pathologic predictor of recurrence, metastasis, and prostate cancer-specific death in patients receiving salvage radiation therapy following radical prostatectomy.
Jackson W; Hamstra DA; Johnson S; Zhou J; Foster B; Foster C; Li D; Song Y; Palapattu GS; Kunju LP; Mehra R; Feng FY
Cancer; 2013 Sep; 119(18):3287-94. PubMed ID: 23821578
[TBL] [Abstract][Full Text] [Related]
3. Gleason pattern 5 is the greatest risk factor for clinical failure and death from prostate cancer after dose-escalated radiation therapy and hormonal ablation.
Sabolch A; Feng FY; Daignault-Newton S; Halverson S; Blas K; Phelps L; Olson KB; Sandler HM; Hamstra DA
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e351-60. PubMed ID: 21493015
[TBL] [Abstract][Full Text] [Related]
4. Impact of Gleason pattern 5 including tertiary pattern 5 on outcomes of salvage treatment for biochemical recurrence in pT2-3N0M0 prostate cancer.
Taguchi S; Shiraishi K; Fukuhara H; Nakagawa K; Morikawa T; Naito A; Kakutani S; Takeshima Y; Miyazaki H; Nakagawa T; Fujimura T; Kume H; Homma Y
Int J Clin Oncol; 2016 Oct; 21(5):975-980. PubMed ID: 27098807
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy improves prostate cancer survival for patients with potentially lethal prostate cancer: The impact of Gleason pattern 5.
Liss AL; Abu-Isa EI; Jawad MS; Feng FY; Vance SM; Winfield RJ; Narayana V; Sandler HM; McLaughlin PW; Hamstra DA
Brachytherapy; 2015; 14(4):502-10. PubMed ID: 25911994
[TBL] [Abstract][Full Text] [Related]
6. Interval to biochemical failure predicts clinical outcomes in patients with high-risk prostate cancer treated by combined-modality radiation therapy.
Shilkrut M; McLaughlin PW; Merrick GS; Vainshtein JM; Feng FY; Hamstra DA
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):721-8. PubMed ID: 23664325
[TBL] [Abstract][Full Text] [Related]
7. Ki-67 is an independent predictor of metastasis and cause-specific mortality for prostate cancer patients treated on Radiation Therapy Oncology Group (RTOG) 94-08.
Verhoven B; Yan Y; Ritter M; Khor LY; Hammond E; Jones C; Amin M; Bahary JP; Zeitzer K; Pollack A
Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):317-23. PubMed ID: 23474109
[TBL] [Abstract][Full Text] [Related]
8. Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era.
Kupelian PA; Buchsbaum JC; Patel C; Elshaikh M; Reddy CA; Zippe C; Klein EA
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):704-11. PubMed ID: 11849793
[TBL] [Abstract][Full Text] [Related]
9. Retrospective evaluation reveals that long-term androgen deprivation therapy improves cause-specific and overall survival in the setting of dose-escalated radiation for high-risk prostate cancer.
Feng FY; Blas K; Olson K; Stenmark M; Sandler H; Hamstra DA
Int J Radiat Oncol Biol Phys; 2013 May; 86(1):64-71. PubMed ID: 23462420
[TBL] [Abstract][Full Text] [Related]
10. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
[TBL] [Abstract][Full Text] [Related]
11. Impact of ultrahigh baseline PSA levels on biochemical and clinical outcomes in two Radiation Therapy Oncology Group prostate clinical trials.
Rodrigues G; Bae K; Roach M; Lawton C; Donnelly B; Grignon D; Hanks G; Porter A; Lepor H; Sandler H
Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):445-52. PubMed ID: 20615632
[TBL] [Abstract][Full Text] [Related]
12. Very High-Risk Localized Prostate Cancer: Outcomes Following Definitive Radiation.
Narang AK; Gergis C; Robertson SP; He P; Ram AN; McNutt TR; Griffith E; DeWeese TA; Honig S; Singh H; Song DY; Tran PT; DeWeese TL
Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):254-62. PubMed ID: 26853334
[TBL] [Abstract][Full Text] [Related]
13. Importance of Local Control in Early-Stage Prostate Cancer: Outcomes of Patients With Positive Post-Radiation Therapy Biopsy Results Treated in RTOG 9408.
Krauss DJ; Hu C; Bahary JP; Souhami L; Gore EM; Chafe SM; Leibenhaut MH; Narayan S; Torres-Roca J; Michalski J; Zeitzer KL; Donavanik V; Sandler H; McGowan DG; Jones CU; Shipley WU
Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):863-73. PubMed ID: 26104939
[TBL] [Abstract][Full Text] [Related]
14. Older age predicts decreased metastasis and prostate cancer-specific death for men treated with radiation therapy: meta-analysis of radiation therapy oncology group trials.
Hamstra DA; Bae K; Pilepich MV; Hanks GE; Grignon DJ; McGowan DG; Roach M; Lawton C; Lee RJ; Sandler H
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1293-301. PubMed ID: 21458924
[TBL] [Abstract][Full Text] [Related]
15. The need for more aggressive therapy for men with Gleason 9-10 disease compared to Gleason ≤8 high-risk prostate cancer.
Safdieh JJ; Schwartz D; Weiner JP; Nwokedi E; Schreiber D
Tumori; 2016; 102(2):168-73. PubMed ID: 26917408
[TBL] [Abstract][Full Text] [Related]
16. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.
Vargas C; Martínez A; Galalae R; Demanes J; Harsolia A; Schour L; Nuernberg N; Gonzalez J
Prostate Cancer Prostatic Dis; 2006; 9(3):245-53. PubMed ID: 16786040
[TBL] [Abstract][Full Text] [Related]
17. Radiotherapy doses of 80 Gy and higher are associated with lower mortality in men with Gleason score 8 to 10 prostate cancer.
Pahlajani N; Ruth KJ; Buyyounouski MK; Chen DY; Horwitz EM; Hanks GE; Price RA; Pollack A
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1949-56. PubMed ID: 21763081
[TBL] [Abstract][Full Text] [Related]
18. The percent of positive biopsy cores improves prediction of prostate cancer-specific death in patients treated with dose-escalated radiotherapy.
Qian Y; Feng FY; Halverson S; Blas K; Sandler HM; Hamstra DA
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e135-42. PubMed ID: 21345617
[TBL] [Abstract][Full Text] [Related]
19. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy.
Jackson WC; Schipper MJ; Johnson SB; Foster C; Li D; Sandler HM; Palapattu GS; Hamstra DA; Feng FY
Eur Urol; 2016 Jan; 69(1):50-7. PubMed ID: 26004800
[TBL] [Abstract][Full Text] [Related]
20. Percentage of positive biopsy cores: a better risk stratification model for prostate cancer?
Huang J; Vicini FA; Williams SG; Ye H; McGrath S; Ghilezan M; Krauss D; Martinez AA; Kestin LL
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1141-8. PubMed ID: 22099043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
